Lexicon Pharmaceuticals
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 1995-01-01
- Employees
- 285
- Market Cap
- $621.7M
- Website
- http://www.lexpharma.com
- Introduction
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
- Conditions
- Obstructive Cardiomyopathy, HypertrophicNon-obstructive Hypertrophic Cardiomyopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT06481891
- Locations
- πΊπΈ
Lexicon Investigational Site (4021), Baltimore, Maryland, United States
πΊπΈLexicon Investigational Site (4038), Grand Rapids, Michigan, United States
πΊπΈLexicon Investigational Site (4040), Milwaukee, Wisconsin, United States
A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- Drug: LX9211 (blinded)Drug: Placebo (blinded)
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 496
- Registration Number
- NCT06203002
- Locations
- πΊπΈ
Lexicon Investigational Site (128), Anniston, Alabama, United States
πΊπΈLexicon Investigational Site (128), Anniston, Alabama, United States
πΊπΈLexicon Investigational Site (222), Birmingham, Alabama, United States
Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 79
- Registration Number
- NCT04662281
- Locations
- πΊπΈ
Lexicon Investigational Site, Kenosha, Wisconsin, United States
πΊπΈLexicon Investigational Site (113), Miami, Florida, United States
πΊπΈLexicon Investigational Site (147), Marietta, Georgia, United States
Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
- Conditions
- Diabetic Peripheral NeuropathyDiabetes
- Interventions
- Drug: LX9211 Matching Placebo
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 319
- Registration Number
- NCT04455633
- Locations
- πΊπΈ
Lexicon Investigational Site, Renton, Washington, United States
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
- Conditions
- Type 2 Diabetes MellitusHeart Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 1222
- Registration Number
- NCT03521934
- Locations
- πΊπΈ
Investigational Site Number 8400128, Alexander City, Alabama, United States
πΊπΈInvestigational Site Number 8400109, Cottonwood, Arizona, United States
πΊπΈInvestigational Site Number 8400032, Little Rock, Arkansas, United States
Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT03423446
- Locations
- πΊπΈ
Lexicon Investigational Site, San Antonio, Texas, United States
Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 376
- Registration Number
- NCT03386344
- Locations
- πΊπΈ
Investigational Site Number 8409009, Escondido, California, United States
πΊπΈInvestigational Site Number 8409010, Greenbrae, California, United States
πΊπΈInvestigational Site Number 8409005, Walnut Creek, California, United States
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 770
- Registration Number
- NCT03351478
- Locations
- πΊπΈ
Investigational Site Number 8408035, Birmingham, Alabama, United States
πΊπΈInvestigational Site Number 8408028, Sheffield, Alabama, United States
πΊπΈInvestigational Site Number 8408047, Hawaiian Gardens, California, United States
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 954
- Registration Number
- NCT03332771
- Locations
- πΊπΈ
Investigational Site Number 8407040, Birmingham, Alabama, United States
πΊπΈInvestigational Site Number 8407048, Birmingham, Alabama, United States
πΊπΈInvestigational Site Number 8407035, Little Rock, Arkansas, United States
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
- Conditions
- Chronic Kidney DiseasesType 2 Diabetes MellitusHeart Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 10584
- Registration Number
- NCT03315143
- Locations
- πΊπΈ
Investigational Site Number 8400017, Birmingham, Alabama, United States
πΊπΈInvestigational Site Number 8400096, Sheffield, Alabama, United States
πΊπΈInvestigational Site Number 8400004, Mesa, Arizona, United States